This is the authors' abstract. We don't add key points for this paper.
// Bindong Dai 1 , Yan Hu 1 , JinHong Duan 1 , Xian-Da Yang 1 1 Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China Correspondence to: Xian-Da Yang, e-mail: ayangmd@gmail.com Keywords: MUC1, aptamer, DNA tetrahedron, targeted drug delivery, cancer Received: January 26, 2016 Accepted: May 01, 2016 Published: May 18, 2016 ABSTRACT Mucin 1 (MUC1) is an important molecular target for cancer treatment because it is overexpressed in most adenocarcinomas. In this study, a new MUC1-targeted drug delivery system was assembled using an aptamer (Apt) that could recognize MUC1 and a DNA tetrahedron (Td) that could carry doxorubicin (Dox) within its DNA structure. The complex thus formed (Apt-Td) had an average size of 12.38 nm and was negatively charged. Similar to the MUC1 aptamer, the Apt-Td could preferentially bind with MUC1-positive MCF-7 breast cancer cells. A drug loading experiment revealed that each Apt-Td complex could carry approximately 25 Dox molecules. Moreover, Apt-Td selectively delivered Dox into the MUC1-positive breast cancer cells but reduced Dox uptake by the MUC1-negative control cells. Dox-loaded Apt-Td also induced a significantly higher cytotoxicity to the MUC1-positive cancer cells versus the MUC1-negative control cells in vitro (p<0.01). These results suggest that Apt-Td may potentially serve as a drug carrier in the targeted treatment of MUC1-expressing breast cancers.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: